Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Dementia with Lewy bodies ... so the discovery that commonly used drugs may reduce the risk of the disease is a beacon of hope for patients and their carers. The main finding of the observational ...

The average life expectancy of people diagnosed with dementia ranges from nine years at age 60 to 4.5 years at age 85 for ...

Previous research has associated sleep medications with other health risks, such as falls, fractures, car accidents, and ...

Ozempic could help patients with advanced Alzheimer’s disease, scientists believe. Trials are underway examining the impact of semaglutide – marketed as Ozempic for the treatment of diabetes and ...

Researchers at the University of Nottingham discovered that anticholinergic drug use is linked to an ... to almost a 50% increase in risk of dementia among patients aged 55 and over.

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to ...

In this prognostic study, with the use of a statistical modeling approach, the Florey Dementia Index was developed and validated to predict the onset age of mild cognitive impairment and Alzheimer ...